Nichi-Iko Has An Ally In Argentina On Infliximab
Strikes Deal With Laboratorio Elea To Market Remicade Biosimilar
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
You may also be interested in...
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Japan’s Nichi-Iko has reported operating profit that has plummeted by more than 95% in its latest financial year, as the firm suffered a forced shutdown of once of its Japanese plants and also recognized a substantial impairment linked to its US Sagent business.
Nichi-Iko maintains it is still on course to be one of the very few players to offer an ‘interchangeable’ biosimilar in the US, with its rival to Janssen’s Remicade. The Japanese company has revealed its latest schedule as it also reported full-year financial results.